AXIS Capital Holdings Limited, through its subsidiaries, provides various specialty insurance and reinsurance products in Bermuda, the United States, and internationally. It operates through two segments, Insurance and Reinsurance. The Insurance segment offers professional insurance products that cover directors' and officers' liability, errors and omissions, employment practices, fiduciary, crime, professional indemnity, medical malpractice, and other financial insurance related coverages for commercial enterprises, financial institutions, not-for-profit organizations, and other professional service providers; and property insurance products for commercial buildings, residential premises, construction projects, property in transit, onshore renewable energy installations, and physical damage and business interruption following an act of terrorism. This segment also provides marine and aviation insurance services for offshore energy, offshore renewable energy, cargo, liability, including kidnap and ransom, fine art, specie, and hull war, hull and liability, and specific war coverage for passenger airlines, cargo operations, general aviation operations, airports, aviation authorities, security firms, and  product manufacturers; personal accident, travel insurance, specialty health products for employer and affinity groups, and pet insurance products; and liability, cyber, and credit and political risk insurance services. The Reinsurance segment offers agriculture, marine and aviation, catastrophe, accidental and health, credit and surety, motor, professional, travel, life, engineering, property, and liability reinsurance products. AXIS Capital Holdings Limited was founded in 2001 and is headquartered in Pembroke, Bermuda.

Axis Capital Holdings Limited

NAXS AB ( ($SE:NAXS) ) just unveiled an update. NAXS AB has repurchased 4,329 of its own shares on Nasdaq Stockholm between 18 and 22 May 2026 as p...

NAXS Steps Up Share Buybacks to Optimize Capital Structure

Axis Capital ( ($AXS) ) just unveiled an announcement. At its Annual General Meeting of Shareholders held on May 14, 2026, AXIS Capital shareholder...

AXIS Capital shareholders affirm directors, pay and auditor

NAXS AB ( ($SE:NAXS) ) has issued an update. NAXS AB has continued its share repurchase program, buying back 4,029 shares on Nasdaq Stockholm betwe...

NAXS Strengthens Capital Management with Ongoing Share Buybacks

The latest announcement is out from NAXS AB ( ($SE:NAXS) ). NAXS AB has repurchased 3,970 of its own shares on Nasdaq Stockholm between 4 and 8 May...

NAXS Steps Up Share Buybacks to Tighten Capital Structure and Boost Returns

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics today and set a price target of $310.00. Suvannavejh cov...

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Morgan Stanley analyst Sean Laaman maintained a Hold rating on Axsome Therapeutics today and set a price target of $242.00. According to TipRanks, ...

Morgan Stanley Sticks to Its Hold Rating for Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Travere Therapeutics (TVTX) and Axsome Therapeutics ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Axsome Therapeutics Inc. (($AXSM)) has held its Q1 earnings call. Read on for the main highlights of the call. Axsome Therapeutics Inc. struck an u...

Axsome Therapeutics Earnings Call Signals Aggressive Growth

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evotec AG (EVO), Twist Bioscience (TWST) and Axsome ...

Analysts Offer Insights on Healthcare Companies: Evotec AG (EVO), Twist Bioscience (TWST) and Axsome Therapeutics (AXSM)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arvinas Holding Company (ARVN) and Axsome Therapeuti...

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and Axsome Therapeutics (AXSM)

Axsome Therapeutics ( ($AXSM) ) just unveiled an update. On May 4, 2026, Axsome Therapeutics reported first quarter 2026 net product revenue of $19...

Axsome Highlights Strong Q1 Growth and AUVELITY Expansion

There’s a lot to be optimistic about in the Financial sector as 3 analysts just weighed in on Axis Capital (AXS), KeyCorp (KEY) and Ares Management...

Analysts Offer Insights on Financial Companies: Axis Capital (AXS), KeyCorp (KEY) and Ares Management (ARES)

NAXS AB ( ($SE:NAXS) ) just unveiled an update. NAXS AB has repurchased 3,537 of its own shares between 27 and 30 April 2026 under an ongoing buyba...

NAXS expands share buyback to bolster capital structure and shareholder value

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM) and Kymera Therapeutics (...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM) and Kymera Therapeutics (KYMR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Evommune, Inc. (EVMN) an...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Evommune, Inc. (EVMN) and Alnylam Pharma (ALNY)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incy...

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intellia Therapeutics (NTLA) and Incyte (INCY)

NAXS AB ( ($SE:NAXS) ) has shared an update. NAXS AB, the Stockholm-listed investment company focused on Nordic private equity, targets long-term v...

Market Cap	$7.38B	P/E Ratio	7.46
52W High	$110.34	52W Low	$88.07
Div Yield	176.0%	Payout Ratio	13.3%
EPS Growth 3Y	N/A	52W Position	49.0%
Overall Score	50	Value Score	80
Quality Score	52	Technical Score	20

EPS Current Est	$13.26	EPS Next Est	$14.39
EPS Growth Est	+8.5%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AXS	$98.98	-0.96%	406.70K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AXS	$98.98	-1.0%	406.70K
3
4
5
6

AXS

AXS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Axis Capital Holdings Limited Data in Excel

Get Axis Capital Holdings Limited Data in Excel